Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro

Anti-Cancer Drugs

Volumn 8, Issue 1, 1997, Pages 34-41

  Fulda, S ^b   Oster, W ^a   Berthold, F ^b  

^a USB Pharma Ltd   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

alkylating agents; antibiotics; antineo plastic; chemoprotection; cisplatin compounds; etoposide; neuroblastoma; tumor cells cultured; vinca alkaloids; WR 1065; WR 2721

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 4 HYDROPEROXYIFOSFAMIDE; AMIFOSTINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; HUMAN; HUMAN CELL; NEUROBLASTOMA; ONCOGENE MYC; PRIORITY JOURNAL; TUMOR CELL LINE;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; MERCAPTOETHYLAMINES; NEUROBLASTOMA; RADIATION-PROTECTIVE AGENTS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031052505     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199701000-00004     Document Type: Article

References (34)

1. Davidson DE, Grenan MM, Sweeney TR. Biological characteristics of some improved radioprotectors. In: Prady LN, ed., Radiation sensitizers. New York: Masson 1980: 302-20.
2. Shaw LM, Turrisi AT, Glover DJ, et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 1986; 12: 1501-4.
3. Shaw LM, Glover DJ, Turrisi A, et al. Pharmacokinetics of WR-2721. Pharmac Ther 1988; 39: 195-201.
4. Shaw L, Bonner H, Nakashima H, Lieberman R. Pharmacokinetics of amifostine in cancer patients: evidence for saturable metabolism. Proc Am Soc Clin Oncol 1994; 13: 144.
5. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988; 48: 3634-40.
6. Smoluk GD, Fahey RC, Calabro-Jones PM, Aguilera JA, Ward JF. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res 1988; 48: 3641-7.
7. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF, Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985; 47: 23-7.
8. Grdina DJ, Sigdestad CP Radiation protors: the unexpected benefits. Drug Metab Rev 1989; 20: 13-42.
9. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980; 3: 211-6.
10. Millar JL, McElwain TJ, Clutterbuck RD, Wist EA. The modification of melphalan toxicity in tumor bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721). Am J Clin Oncol (CCT) 1982; 5: 321-8.
11. Mitchell JLA, Judd GG, Diveley RR, Choe CY, Leyser A. Involvement of the polyamine transport system in cellular uptake of the radioprotectants WR-1065 and WR-33278. Carcinogenesis 1995; 16: 3063-8.
12. Murley JS, Grdina DJ. The effects of cycloheximide and WR-1065 on radiation-induced repair processes: a mechanism for chemoprevention. Carcinogenesis 1995; 16: 2699-705.
13. Hülsewede JW, Schulte-Frohlinde D. Radiation protection of E. coli strains by cysteamine in the presence of oxygen. Int J Radiat Biol 1986; 50: 861-9.
14. Grdina DJ, Nagy B, Meechan P. Effect of an aminothiol (WR-1065) on radiation-induced mutagenesis and cytotoxicity in two repair-deficient mammalian cell lines. In Nygaard OF, Upton AC, eds. Anticarcinogenesis and radiation protection 2. New York: Plenum Press 1991.
15. Bresler SE, Noskin LA, Stepanova IM, Kuzovlena NA. Mechanism of the radioprotecting action of chemical compounds on Escherichia coli cells. Mol Gen Genet 1978; 163: 75-85.
16. Petin VG, Matrenina VL. Radioprotecting action of chemical compounds on γ-irradiated yeast cells of various genotypes. Mol Gen Genet 1981; 183: 152-7.
17. Schwab M. Amplification of MYCN in human neuroblastoma. Trends Genet 1985; 1: 271-5.
18. Dietel M, Bals U, Schaefer B, Herzig I, Arps H, Zabel M. In vitro prediction of cytostatic drug resistance in primary cell cultures of solid malignant tumors. Eur J Cancer 1993; 29A: 416-20.
19. Giles KW, Myers A. An improved diphenylamine method for the estimation of desoxyribonucleic acid. Nature 1965; 206: 93.
20. Fulda S, Honer M, Menke-Moellers I, Berthold F. Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Eur J Cancer 1995; 31A: 616-21.
21. Young JC, Ries LG, Silverberg E, Horm JW, Miller, RW Cancer incidence, survival and mortality for children younger than age 15 years. Cancer 1986; 58: 598-602.
22. Valeriote F, Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 1982; 42: 4330-1.
23. Yuhas JM, Culo F. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its anti-tumor properties. Cancer Treat Rep 1980; 64: 57-64.
24. Milas L, Hunter NR, Stephens LC, Peters LJ. Inhibition of radiation carcinogenesis in mice by S-2-(3-Aminopropylamino)-ethylphosphorothioic acid. Cancer Res 1984; 44: 5567-9.
25. Meagher RC, Rothman SA, Paul P, Koberna P, Willmer C, Baucco PA. Purging of small cell lung cancer cells from human bone marrow using ethiofos (WR-2721) and light-activated merocyanine 540 phototreatment. Cancer Res 1989; 49: 3637-41.
26. Millar JL, Clutterbuck RD. The effect of WR-2721 on melphalan toxicity in mice. Br J Cancer 1982; 45: 633.
27. Treskes M, Boven E, Loosdrecht AA, et al. Effects of the modulating agent WR-2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 1994; 30: 183-7.
28. Wittenkeller J, Bittner G, Schiller JH. Amifostine (WR-2721) enhances cisplatinum/vinblastine effect on non-small cell lung carcinoma cells in vivo but not in vitro. Proc Am Ass Cancer Res 1994; 35: 386 (2298A).
29. Gorin NC, Douay L, Laporte JP, et al. Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia. Blood 1986; 67: 1367-76.
30. Laporte JP, Douay L, Lopez M, et al. 125 Adult patients with primary leukemia autografted with marrow pursed by mafosfamide: a 10-year single institution experience. Blood 1994; 84: 3810-8.
31. Douay L, Hu C, Giarratana M, Bouchet S, Conlon J, Capizzi RL, Gorin N-C. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 1995; 86: 2849-55.
32. Korst AEC, Kedde MA, Eeltink CM, Vermorken JB, van der Vijgh WJF. Pharmacokinetics of amifostine and its metabolites in plasma and ascites of patients. Proc Am Ass Cancer Res 1995; 36: abstr 1728.
33. Adamson PC, Balis FM, Belasco JE, et al. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 1995; 55: 4069-72.
34. Borsi JD, Csáki C, Ferencz T, Oster W. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Anti-Cancer Drugs 1996; 7: 121-6.